Lund, Sweden, November 3, 2021– Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the Nomination Committee in preparation for the Annual General Meeting (AGM) on May 5, 2022, has been appointed.
Pursuant to the instruction for the Nomination Committee adopted by the AGM on June 1, 2021, the Nomination Committee for the Alligator Bioscience AGM 2022 shall consist of four members, representing the three largest shareholders at the last weekday of June, together with the Chairman of the Board. If a shareholder does not exercise its right to appoint a member, entitlement to appoint a member of the Nomination Committee transfers to the shareholder who is the next largest shareholder in terms of voting rights.
Based on the above, the Nomination Committee for the AGM 2022 has been established to consist of the following persons, together representing approximately 20 percent of the shares and votes in the company as per the end of June 2021:
– Lars Bergkvist, representing Jonas Sjögren;
– Claus Asbjörn Andersson, representing Sunstone Life Science Ventures II K/S;
– Hans-Peter Ostler, representing Lars Spånberg; and
– Anders Ekblom, Chairman of the Board.
Lars Bergkvist has been appointed Chairman of the Nomination Committee.
The task of the Nomination Committee’s prior to AGM is to prepare and submit proposals regarding the Chairman of the AGM, the number of Board members elected by the AGM, the Chairman and other Board members elected by the AGM, the fees and other remuneration for each of the Board members elected by the AGM and for members of Board committees, the number of auditors, the auditors, the fee for auditors and election of a Nomination Committee, or alternatively a decision on principles for appointing a Nomination Committee, as well as instructions for the Nomination Committee.
Shareholders wishing to submit proposals or comments to the Nomination Committee may do so via email to info@alligatorbioscience.com marked “Att. Nomination committee” or by letter to Alligator Bioscience AB, Nomination Committee, Medicon Village, 223 81 Lund, Sweden. To ensure that the proposals can be considered by the Nomination Committee, proposals shall be submitted in due time before the Annual General Meeting, but not later than 31 January 2022.
The Nomination Committee's proposals will be presented in the notice convening the AGM and on the company's website.
For further information:
Julie Silber, Director Investor Relations & Communications
Phone +: +46 46-540 82 23
E-mail: jur@alligatorbioscience.com
The information was submitted for publication, through the agency of the contact person set out above, at 3:00 p.m. CET on November 3, 2021.
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, with MacroGenics Inc. and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden. For more information, please visit http://www.alligatorbioscience.com.